期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分化型甲状腺癌术后患者131I治疗的辐射剂量与防护 被引量：5

Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment
原文传递
导出
摘要 监测分化型甲状腺癌（DTC）患者术后131I治疗的辐射剂量并规范其辐射防护对DTC患者131I治疗后自身及周围人群的健康有重要意义.目前研究表明,131I治疗的DTC患者自身的辐射不良反应大多都能得到较有效地缓解和控制.只要能严格规范地遵守131I治疗DTC的辐射防护相关法规和建议,加强辐射剂量监测,并对患者、工作人员和患者家属进行适当的教育和指导,其对周围人群的辐射剂量都能达到和符合国际上的辐射防护规定. It is of great significance to monitor radiation dose and standardize radiation protection of differentiated thyroid carcinoma （DTC） patients after 131I treatment.It can protect patients and the surrounding people from radiation risks.The present study showed that the adverse reactions can be alleviated and controlled effectively in DTC patients after 131I treatment.The radiation dose of the surrounding people can be in line with the international radiation protection regulations,as long as the related laws and regulations of radiation protection in 131I treatment can be strictly obeyed,as well as the radiation dose is monitored and the right guidance and instructions are given to the patients,staff and family members.
作者 成钊汀 谭建
机构地区 天津医科大学总医院核医学科
出处 《国际放射医学核医学杂志》 2014年第2期110-116,共7页 International Journal of Radiation Medicine and Nuclear Medicine
关键词 甲状腺肿瘤 碘放射性同位素 近距离放射疗法 辐射剂量 辐射防护 Thyroid neoplasms Iodine radioisotopes Brachytherapy Radiation dosage Radiation protection
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献53

  • 1中华人民共和国国家质量监督检验检疫总局.GBl8871-2002电离辐射防护与辐射源安全基本标准[S].北京:中国标准出版社,2003.
  • 2International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides[R]. ICRP Publication 94. Ann ICRP, 2004, 34(2): v-vi,I-79.
  • 3European Commission. Radiation protection 97: radiation protection following iodine-Bl therapy (exposures due to outpatients or discharged inpatients) [R]. Belgium: Office for Official Publications of the European Communities, 1998.
  • 4Vetter RJ. Regulations for radioiodine therapy in the United States: current status and the process of change[J]. Thyroid, 1997,7 (2): 209-21l.
  • 5International Atomic Energy Agency. Nuclear medicine resources manual[R]. Vienna: International Atomic Energy Agency, 2006.
  • 69='$~"M~pq:5t1￡'''MH:, 9='$~~~)7~f4~:5t~, 9=' OOtJi:Jlli ~~*.~.~~~~~, .. ~~.M~~:5t~m~~.Jlli iMitfEiJ￥J[J]. 9=' OO~"'.Ih'li,,*, 2012, 39( 17): 1249-1272.
  • 7Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma[J]. J Clin Endocrinol Metab, 2002, 87(12): 5817-5820.
  • 8Jeong SY, Kim HW, Lee SW, et al. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms[J]. Thyroid, 2013, 23(5): 609-616.
  • 9Kolber! KS, Pentlow KS, Pearson JR, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 1311 by use of 1"'1 PET and 3-dimensional internal dosimetry software[J]. J Nucl Med, 2007, 48(1): 143-149.
  • 10Jentzen W, Schneider E, Freudenberg L, et al. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer[J]. Nucl Med Commun,2006,27(8): 669-676.

二级参考文献12

  • 1刘树铮.低水平辐射对健康的影响[J].核技术,1994,17(6):381-384. 被引量：12
  • 2孙传政,陈福进,曾宗渊,宋明,李秋梨,杨安奎,张诠,魏茂文,伍国号.少年和青年分化型甲状腺癌的生存分析[J].中华耳鼻咽喉头颈外科杂志,2005,40(8):595-600. 被引量：27
  • 3闵锐,潘真,李雨.急性放射病的分度和治疗——介绍美国国家战略储备辐射工作组关于急性放射病治疗的建议之二[J].国外医学（放射医学核医学分册）,2005,29(6):272-278. 被引量：6
  • 4蒋定文,雷呈祥,贾福星,沈先荣,杨翊方,鲁永杰,马丽,张爱兵,刘琼.低剂量率中子长期照射对大鼠外周血白细胞的影响[J].海军医学杂志,2007,28(1):10-11. 被引量：14
  • 5HALAC I, ZIMMERMAN D. Thyroid nodules and cancers in children[J]. Edocrinol Metab Clin North Am, 2005, 34(3):725-744.
  • 6JARZAB B, HANDKIEWICZ-JUNAK D. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment, A qualitative review [J].Endocr Relat Cancer, 2005, 12(4):773-803.
  • 7DOUGLAS VAN NOSTRAND. The benefits and risks of ^131I therapy in patients with well-different thyroid cancer[J]. Thyroid, 2009, 19:1381-1391.
  • 8VAN NOSTRAND D, FREITAS J. Thyroid Cancer: A comprehensive guide to clinical management, side effects of I-131 for ablation and treatment of well- differentiated thyroid carcinoma [M]. Totowa, NJ, Humana Press, 2006, 459-484.
  • 9DE KEIZER B, HOEKSTRA A, KONIJNENBERG M W,et al. Bone marrow dosimetry and safety of high ^131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer [ J ]. J Nucl Med,2004, 45(9) ,1549-1555.
  • 10BENUA R S, CICALE N R, SONENBERG M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer[J]. Am J Roentgenol Radium Ther Nucl Med,1962,87:171-182.

共引文献7

同被引文献38

  • 1李少林,王荣福.核医学[M].7版.北京:人民卫生出版社,2008:88.
  • 2Cooper DS, Doherty GM, Haugen BR, et al. Management guide- lines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2006, 16(2): 109-142.
  • 3Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thy- roid nodules and differentiated thyroid cancer[ J ]. Thyroid, 2009, 19(11): 1167 -1214.
  • 4Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioac- tive iodine remnant ablation : using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system[ J]. Thyroid, 2010, 20(12) : 1341 - 1349.
  • 5Vetter RJ. Regulations for radioiodine therapy in the United States: current status and the process of change [ J]. Thyroid, 1997, 7(2) : 209 -211.
  • 6Ross DS, Ridgway EC, Daniels GH. Successful treatment of soli- tary toxic thyroid nodules with relatively low - dose iodine - 131, with low prevalence of hypothyroidism [ J ]. Ann Intern Med, 1984, 101(4) : 488 -490.
  • 7Watanabe H. Explanation of the draft, "release of patients after therapy with unsealed radionuclides" of the International Commis- sion on Radiological Protection: the 2nd report[ J]. Nihon Hosha- sen Gijatsu Gakkai Zasshi, 2004, 60(5): 689-697.
  • 8Kusakabe K, Yokoyama K, ho K, et al. Thyroid remnant ablation using 1, 110 MBq of I - 131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine the- rapy[J]. Ann Nucl Med, 2012, 26(4) : 370 -378.
  • 9Willegaignon J, Malvestiti LF, Guimaraes MI, et al. 1311 effective half- life (Teff) for patients with thyroid cancer [ J]. Health Phys, 2006, 91(2): 119-122.
  • 10Remy H, Borget I, Leboulleux S, et al. 131I effective half- life and dosimetry in thyroid cancer patients [ J ]. J Nucl Med, 2008, 49(9) : 1445 -1450.

引证文献5

二级引证文献18

国际放射医学核医学杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部